Abstract:Background Short but impactful, the two‐decade story of gene editing allowed a significant breakthrough in the treatment of haematological malignancies. However, despite different generations of chimeric antigen receptor T (CAR T), such a successful therapy has not yet been replicated in solid tumours and non‐oncological diseases. Methods This narrative review discusses how CAR T therapy still faces challenges in overcoming the complexity of the solid tumour microenvironment and the concerns that its long‐term activity raises about potential unknown and unpredictable consequences in non‐oncological diseases. Results In the most recent studies, the senolytic potential of CAR T is becoming an exciting field of research. Still, experimental but promising results indeed indicate the clearance of senescent cells as an effective strategy to improve exercise capacity and metabolic dysfunction in physiological ageing, with long‐term therapeutic and preventive effects. However, an effective expansion of a CAR T population requires a lympho‐depleting chemotherapy prior to infusion. While this procedure sounds reasonable for rescue therapy of oncological diseases, it poses genotoxic risks that may not be justified for non‐malignant diseases. Those represent the leading gaps for applying CAR T therapy in non‐oncological diseases. Conclusion More is expected from current studies on the other classes of CAR cells now under investigation. Engineering NK cells and macrophages are candidates to improve cytotoxic and immunomodulating properties, potentially able to broaden application in solid tumours and non‐oncological diseases. Finally, engineering autologous T cells in old individuals may generate biologically deteriorated CAR T clones with impaired function and unpredictable effects on cytokine release.

T Cell Senescence and CAR-T Cell Exhaustion in Hematological Malignancies

Autophagic Flux Restoration of Senescent T Cells Improves Antitumor Activity of TCR‐engineered T Cells

Reprogramming T cell differentiation and exhaustion in CAR-T cell therapy

Unlocking T cell exhaustion: Insights and implications for CAR-T cell therapy

T cell senescence: a new perspective on immunotherapy in lung cancer

CAR T therapy from haematological malignancies to aging‐related diseases: An ever‐expanding universe

Fine-Tuning through Generations: Advances in Structure and Production of CAR-T Therapy

[Advances in Immunotherapy of Hematological Malignancies by Using Chimeric Antigen Receptor-Modified Lymphocytes].

T-cell exhaustion and stemness in antitumor immunity: Characteristics, mechanisms, and implications

Characteristics and mechanisms of T-cell senescence: A potential target for cancer immunotherapy

Senescent T cells: a potential biomarker and target for cancer therapy

Chimeric antigen receptor-T cell therapy for T cell-derived hematological malignancies

Strategies for Reducing Toxicity and Enhancing Efficacy of Chimeric Antigen Receptor T Cell Therapy in Hematological Malignancies

T cell exhaustion in human cancers

Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion

Genetically Modified T-Cell-Based Adoptive Immunotherapy in Hematological Malignancies

Cell metabolism-based optimization strategy of CAR-T cell function in cancer therapy

T‐cell exhaustion in CAR‐T‐cell therapy and strategies to overcome it

Tumor microenvironment and cellular senescence: Understanding therapeutic resistance and harnessing strategies

Deciphering the impact of TERT/telomerase on immunosenescence and T cell revitalization

Enhancing the Efficacy of CAR-T Cell Therapy: A Comprehensive Exploration of Cellular Strategies and Molecular Dynamics